Literature DB >> 19835865

The role of stromal-derived factor-1--CXCR7 axis in development and cancer.

Radoslaw B Maksym1, Maciej Tarnowski, Katarzyna Grymula, Joanna Tarnowska, Marcin Wysoczynski, Riu Liu, Boguslaw Czerny, Janina Ratajczak, Magda Kucia, Mariusz Z Ratajczak.   

Abstract

Cancer metastasis is a major clinical problem that contributes to unsuccessful therapy. Augmenting evidence indicates that metastasizing cancer cells employ several mechanisms that are involved in developmental trafficking of normal stem cells. Stromal-derived factor-1 (SDF-1) is an important alpha-chemokine that binds to the G-protein-coupled seven-transmembrane span CXCR4. The SDF-1-CXCR4 axis regulates trafficking of normal and malignant cells. SDF-1 is an important chemoattractant for a variety of cells including hematopoietic stem/progenitor cells. For many years, it was believed that CXCR4 was the only receptor for SDF-1. However, several reports recently provided evidence that SDF-1 also binds to another seven-transmembrane span receptor called CXCR7, sharing this receptor with another chemokine family member called Interferon-inducible T-cell chemoattractant (I-TAC). Thus, with CXCR7 identified as a new receptor for SDF-1, the role of the SDF-1-CXCR4 axis in regulating several biological processes becomes more complex. Based on the available literature, this review addresses the biological significance of SDF-1's interaction with CXCR7, which may act as a kind of decoy or signaling receptor depending on cell type. Augmenting evidence suggests that CXCR7 is involved in several aspects of tumorogenesis and could become an important target for new anti-metastatic and anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19835865      PMCID: PMC2783873          DOI: 10.1016/j.ejphar.2009.04.071

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  98 in total

Review 1.  Chemokines on the move: control by the chemokine "interceptors" Duffy blood group antigen and D6.

Authors:  Robert Nibbs; Gerard Graham; Antal Rot
Journal:  Semin Immunol       Date:  2003-10       Impact factor: 11.130

2.  Vascular gene expression in nonneoplastic and malignant brain.

Authors:  Stephen L Madden; Brian P Cook; Mariana Nacht; William D Weber; Michelle R Callahan; Yide Jiang; Michael R Dufault; Xiaoming Zhang; Wen Zhang; Jennifer Walter-Yohrling; Cecile Rouleau; Viatcheslav R Akmaev; Clarence J Wang; Xiaohong Cao; Thia B St Martin; Bruce L Roberts; Beverly A Teicher; Katherine W Klinger; Radu-Virgil Stan; Brenden Lucey; Eleanor B Carson-Walter; John Laterra; Kevin A Walter
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

3.  A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma.

Authors:  M Takenaga; H Tamamura; K Hiramatsu; N Nakamura; Y Yamaguchi; A Kitagawa; S Kawai; H Nakashima; N Fujii; R Igarashi
Journal:  Biochem Biophys Res Commun       Date:  2004-07-16       Impact factor: 3.575

4.  Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.

Authors:  Kacper Jankowski; Magda Kucia; Marcin Wysoczynski; Ryan Reca; Dongling Zhao; Ela Trzyna; John Trent; Stephen Peiper; Marek Zembala; Janina Ratajczak; Peter Houghton; Anna Janowska-Wieczorek; Mariusz Z Ratajczak
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

5.  Tissue-specific muscle, neural and liver stem/progenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during stress and tissue injury.

Authors:  Magda Kucia; Janina Ratajczak; Ryan Reca; Anna Janowska-Wieczorek; Mariusz Z Ratajczak
Journal:  Blood Cells Mol Dis       Date:  2004 Jan-Feb       Impact factor: 3.039

6.  Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization.

Authors:  Thalia Papayannopoulou
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

7.  Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.

Authors:  Merav Darash-Yahana; Eli Pikarsky; Rinat Abramovitch; Evelyne Zeira; Boaz Pal; Rebekah Karplus; Katia Beider; Shani Avniel; Shafika Kasem; Eithan Galun; Amnon Peled
Journal:  FASEB J       Date:  2004-06-04       Impact factor: 5.191

8.  Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.

Authors:  Steven M Devine; Neal Flomenberg; David H Vesole; Jane Liesveld; Daniel Weisdorf; Karin Badel; Gary Calandra; John F DiPersio
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

Review 9.  Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system.

Authors:  Françoise Lazarini; To Nam Tham; Philippe Casanova; Fernando Arenzana-Seisdedos; Monique Dubois-Dalcq
Journal:  Glia       Date:  2003-04-15       Impact factor: 7.452

10.  Regulation of the chemokine receptor CXCR4 by hypoxia.

Authors:  Tiziana Schioppa; Badarch Uranchimeg; Alessandra Saccani; Subhra K Biswas; Andrea Doni; Annamaria Rapisarda; Sergio Bernasconi; Simona Saccani; Manuela Nebuloni; Luca Vago; Alberto Mantovani; Giovanni Melillo; Antonio Sica
Journal:  J Exp Med       Date:  2003-11-03       Impact factor: 14.307

View more
  59 in total

1.  Activation of two distinct Sox9-EGFP-expressing intestinal stem cell populations during crypt regeneration after irradiation.

Authors:  Laurianne Van Landeghem; M Agostina Santoro; Adrienne E Krebs; Amanda T Mah; Jeffrey J Dehmer; Adam D Gracz; Brooks P Scull; Kirk McNaughton; Scott T Magness; P Kay Lund
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-23       Impact factor: 4.052

Review 2.  CXCL12 in control of neuroinflammation.

Authors:  Miljana Momcilović; Marija Mostarica-Stojković; Djordje Miljković
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  CXCR4 in epidermal keratinocytes: crosstalk within the skin.

Authors:  Wendy B Bollag; William D Hill
Journal:  J Invest Dermatol       Date:  2013-11       Impact factor: 8.551

4.  C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer.

Authors:  Travis J Yates; Judith Knapp; Miguel Gosalbez; Soum D Lokeshwar; Christopher S Gomez; Anaid Benitez; Obi O Ekwenna; Ezekiel E Young; Murugesan Manoharan; Vinata B Lokeshwar
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

5.  Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues.

Authors:  Frauke Hoffmann; Wiebke Müller; Dagmar Schütz; Mark E Penfold; Yung H Wong; Stefan Schulz; Ralf Stumm
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

Review 6.  CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.

Authors:  Hyo Jin Lee; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

7.  Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors.

Authors:  Randala Hamdan; Zhichao Zhou; Eugenie S Kleinerman
Journal:  Mol Cancer Ther       Date:  2013-11-26       Impact factor: 6.261

Review 8.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

9.  Differential expression of SDF-1 isoforms in bladder cancer.

Authors:  Miguel Gosalbez; Marie C Hupe; Soum D Lokeshwar; Travis J Yates; John Shields; Muthu K Veerapen; Axel S Merseburger; Charles J Rosser; Mark S Soloway; Vinata B Lokeshwar
Journal:  J Urol       Date:  2013-11-26       Impact factor: 7.450

10.  Expression of stromal cell-derived factor 1 and CXCR7 in papillary thyroid carcinoma.

Authors:  Zhen Liu; Da-Xin Sun; Xu-Yong Teng; Wei-Xue Xu; Xiang-Peng Meng; Bao-Sheng Wang
Journal:  Endocr Pathol       Date:  2012-12       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.